![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dichloroethane | decreases expression | ISO | RGD:1323482 | 6480464 | ethylene dichloride results in decreased expression of METTL21A mRNA | CTD | PMID:28960355 | 1,2-dimethylhydrazine | decreases expression | ISO | RGD:1323482 | 6480464 | 1, 2-Dimethylhydrazine results in decreased expression of METTL21A mRNA | CTD | PMID:22206623 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1602980 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of METTL21A mRNA | CTD | PMID:20106945, PMID:21632981 | 2,3,7,8-Tetrachlorodibenzofuran | increases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:32109520 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:1602980 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of METTL21A mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of METTL21A mRNA | CTD | PMID:28628672 | 4,4'-sulfonyldiphenol | multiple interactions | ISO | RGD:1602980 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of METTL21A mRNA | CTD | PMID:28628672 | all-trans-retinoic acid | decreases expression | ISO | RGD:1602980 | 6480464 | Tretinoin results in decreased expression of METTL21A mRNA | CTD | PMID:23724009 | antirheumatic drug | increases expression | ISO | RGD:1602980 | 6480464 | Antirheumatic Agents results in increased expression of METTL21A mRNA | CTD | PMID:24449571 | aristolochic acid A | decreases expression | ISO | RGD:1602980 | 6480464 | aristolochic acid I results in decreased expression of METTL21A mRNA | CTD | PMID:33212167 | arsane | affects methylation | ISO | RGD:1602980 | 6480464 | Arsenic affects the methylation of METTL21A gene | CTD | PMID:25304211 | arsenic atom | affects methylation | ISO | RGD:1602980 | 6480464 | Arsenic affects the methylation of METTL21A gene | CTD | PMID:25304211 | avobenzone | increases expression | ISO | RGD:1602980 | 6480464 | avobenzone results in increased expression of METTL21A mRNA | CTD | PMID:31016361 | benzo[a]pyrene | increases expression | ISO | RGD:1323482 | 6480464 | Benzo(a)pyrene results in increased expression of METTL21A mRNA | CTD | PMID:21715664, PMID:22228805 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | RGD:1602980 | 6480464 | 7 more ... | CTD | PMID:19150397 | beta-carotene | multiple interactions | ISO | RGD:1323482 | 6480464 | [BCO1 protein affects the susceptibility to beta Carotene] which affects the expression of METTL21A mRNA | CTD | PMID:24657404 | bisphenol A | affects expression | EXP | | 6480464 | bisphenol A affects the expression of METTL21A mRNA | CTD | PMID:25181051 | bisphenol A | multiple interactions | ISO | RGD:1602980 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of METTL21A mRNA | CTD | PMID:28628672 | bortezomib | increases expression | ISO | RGD:1602980 | 6480464 | Bortezomib results in increased expression of METTL21A mRNA | CTD | PMID:20977926 | butanal | increases expression | ISO | RGD:1602980 | 6480464 | butyraldehyde results in increased expression of METTL21A mRNA | CTD | PMID:26079696 | caffeine | decreases phosphorylation | ISO | RGD:1602980 | 6480464 | Caffeine results in decreased phosphorylation of METTL21A protein | CTD | PMID:35688186 | clofibrate | decreases expression | ISO | RGD:1323482 | 6480464 | Clofibrate results in decreased expression of METTL21A mRNA | CTD | PMID:23811191 | copper(II) sulfate | decreases expression | ISO | RGD:1602980 | 6480464 | Copper Sulfate results in decreased expression of METTL21A mRNA | CTD | PMID:19549813 | crocidolite asbestos | decreases expression | ISO | RGD:1602980 | 6480464 | Asbestos, Crocidolite results in decreased expression of METTL21A mRNA | CTD | PMID:29523930 | dexamethasone | multiple interactions | ISO | RGD:1602980 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of METTL21A mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of METTL21A mRNA | CTD | PMID:28628672 | dibutyl phthalate | decreases expression | ISO | RGD:1323482 | 6480464 | Dibutyl Phthalate results in decreased expression of METTL21A mRNA | CTD | PMID:21266533 | dorsomorphin | multiple interactions | ISO | RGD:1602980 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | entinostat | multiple interactions | ISO | RGD:1602980 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA | CTD | PMID:27188386 | ethyl methanesulfonate | decreases expression | ISO | RGD:1602980 | 6480464 | Ethyl Methanesulfonate results in decreased expression of METTL21A mRNA | CTD | PMID:23649840 | folic acid | decreases expression | ISO | RGD:1323482 | 6480464 | Folic Acid results in decreased expression of METTL21A mRNA | CTD | PMID:25629700 | gentamycin | decreases expression | EXP | | 6480464 | Gentamicins results in decreased expression of METTL21A mRNA | CTD | PMID:33387578 | hydrogen peroxide | affects expression | ISO | RGD:1602980 | 6480464 | Hydrogen Peroxide affects the expression of METTL21A mRNA | CTD | PMID:21179406 | hydroquinone | decreases expression | ISO | RGD:1602980 | 6480464 | hydroquinone results in decreased expression of METTL21A mRNA | CTD | PMID:31256213 | indometacin | multiple interactions | ISO | RGD:1602980 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of METTL21A mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of METTL21A mRNA | CTD | PMID:28628672 | panobinostat | multiple interactions | ISO | RGD:1602980 | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA | CTD | PMID:27188386 | paracetamol | affects expression | ISO | RGD:1323482 | 6480464 | Acetaminophen affects the expression of METTL21A mRNA | CTD | PMID:17562736 | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of METTL21A mRNA | CTD | PMID:33387578 | paracetamol | increases expression | ISO | RGD:1602980 | 6480464 | Acetaminophen results in increased expression of METTL21A mRNA | CTD | PMID:26690555 | phenylmercury acetate | decreases expression | ISO | RGD:1602980 | 6480464 | Phenylmercuric Acetate results in decreased expression of METTL21A mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | RGD:1602980 | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA | CTD | PMID:27188386 | quercetin | decreases expression | ISO | RGD:1602980 | 6480464 | Quercetin results in decreased expression of METTL21A mRNA | CTD | PMID:21632981 | SB 431542 | multiple interactions | ISO | RGD:1602980 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | senecionine | increases expression | ISO | RGD:1323482 | 6480464 | senecionine results in increased expression of METTL21A protein | CTD | PMID:35357534 | silicon dioxide | increases expression | ISO | RGD:1602980 | 6480464 | Silicon Dioxide analog results in increased expression of METTL21A mRNA | CTD | PMID:25895662 | silicon dioxide | decreases expression | ISO | RGD:1323482 | 6480464 | Silicon Dioxide results in decreased expression of METTL21A mRNA | CTD | PMID:19073995 | temozolomide | decreases expression | ISO | RGD:1602980 | 6480464 | Temozolomide results in decreased expression of METTL21A mRNA | CTD | PMID:31758290 | thioacetamide | decreases expression | EXP | | 6480464 | Thioacetamide results in decreased expression of METTL21A mRNA | CTD | PMID:34492290 | trichostatin A | decreases expression | ISO | RGD:1602980 | 6480464 | trichostatin A results in decreased expression of METTL21A mRNA | CTD | PMID:26272509 | trichostatin A | multiple interactions | ISO | RGD:1602980 | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA | CTD | PMID:27188386 | urethane | decreases expression | ISO | RGD:1602980 | 6480464 | Urethane results in decreased expression of METTL21A mRNA | CTD | PMID:28818685 | valproic acid | decreases expression | ISO | RGD:1323482 | 6480464 | Valproic Acid results in decreased expression of METTL21A mRNA | CTD | PMID:21427059 | valproic acid | affects expression | ISO | RGD:1602980 | 6480464 | Valproic Acid affects the expression of METTL21A mRNA | CTD | PMID:25979313 | valproic acid | decreases expression | ISO | RGD:1602980 | 6480464 | Valproic Acid results in decreased expression of METTL21A mRNA | CTD | PMID:23179753 more ... | valproic acid | multiple interactions | ISO | RGD:1602980 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of METTL21A mRNA | CTD | PMID:27188386 | |